NASDAQ: FBLGFibrobiologics Inc Stock
$10.11-1.57 (-13.44%)
Updated Apr 26, 2024
FBLG Price
$10.11
Fair Value Price
N/A
Market Cap
$329.93M
52 Week Low
$6.53
52 Week High
$55.00
P/E
-14.87x
P/B
263.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
8.43
Operating Cash Flow
-$6M
Beta
-5.24
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FBLG Overview
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FBLG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FBLG is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FBLG is poor value based on its book value relative to its share price (263.31x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
FBLG is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FBLG due diligence checks available for Premium users.
Be the first to know about important FBLG news, forecast changes, insider trades & much more!
FBLG News
Valuation
FBLG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.87x
Industry
14.88x
Market
41.14x
FBLG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
263.31x
Industry
5.85x
FBLG is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FBLG's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.7M
Profit Margin
0%
FBLG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.8M
Liabilities
$10.6M
Debt to equity
8.43
FBLG's short-term assets ($9.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FBLG's short-term assets ($9.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FBLG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$2.0k
Financing
$0.0
FBLG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FBLG vs Biotech Stocks
Fibrobiologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.